EASO Updates Obesity Treatment Algorithm With 2026 Evidence for Weight Loss & Liver Disease

The European Association for the Study of Obesity (EASO) has released a 2026 update to its framework for the pharmacological treatment of obesity and its complications. Published in Nature Medicine on May 13, 2026, the updated framework introduces a refined algorithm designed to help clinicians match obesity medications to the specific health needs of individual patients.

The updated guidance marks a strategic shift in clinical approach, moving beyond a primary focus on weight loss alone. The 2026 framework instead encourages a comprehensive evaluation of a patient’s complications, biological mechanisms, and specific treatment goals to determine the most appropriate pharmacological intervention.

A Shift Toward Personalized Treatment

The core objective of the revised algorithm is the transition to personalized care. According to the EASO, the central message within the algorithm is that pharmacological obesity management should be personalised.

Under this personalized model, treatment decisions are not based solely on body weight outcomes. Clinicians are advised to consider the presence and severity of various obesity-related complications when selecting a medication. These complications include:

• Type 2 diabetes
• Cardiovascular diseases
• Heart failure
• Obstructive sleep apnoea
• Knee osteoarthritis
• MASLD/MASH

Evidence Base and Clinical Focus

The 2026 update is based on a review of 62 randomised controlled trials, incorporating clinical evidence published up to November 21, 2025. This evidence base reflects the rapidly evolving landscape of obesity medications, with a particular emphasis on the evidence for incretin-based therapies.

Regarding weight reduction, the framework notes that all medications assessed in the review demonstrated clinically meaningful benefit compared to placebo for total body weight loss. The update further clarifies the comparative parameters of the available medications to better support clinical decision-making.

Expanded Scope for Liver Disease

A significant component of the 2026 update is the expansion of the liver disease domain. The refined algorithm now incorporates evidence regarding MASH resolution and introduces liver fibrosis improvement as a new consideration for 2026.

This expansion allows clinicians to better target pharmacological treatments for patients suffering from metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH), integrating liver health more deeply into the overall obesity management strategy.

A Dynamic Clinical Resource

Launched at ECO2026 in May 2026, the updated framework is intended to function as a flexible resource that evolves alongside medical research. The EASO intends for the algorithm to remain current as new formulations and trials emerge.

The 2026 update confirms EASO’s intention to maintain the pharmacological framework as a living evidence map, updated as new trials, outcomes, medications and formulations emerge.

European Association for the Study of Obesity (EASO)

By maintaining the framework as a living map, the association aims to provide practitioners with a practical, evidence-informed tool that can be adjusted as the evidence base for obesity management medications continues to expand.